Abstract
In this randomized, multicentered study, 157 males and 130 females with laboratory-confirmed, uncomplicated anogenital Neisseria gonorrhoeae infections were evaluated to determine the efficacy and safety of a single 300-mg oral dose of rosoxacin versus 3.5 g of ampicillin plus 1 g of probenecid. A total of 130 males and 101 females were evaluated. Rosoxacin cured 90.3% (P = 0.053) and 94.1% (P = 0.62), respectively, whereas ampicillin was effective in 98.5 and 98% of males and females, respectively. All 39 patients with anorectal infections were cured. One penicillinase-producing N. gonorrhoeae strain was isolated and was eradicated with rosoxacin. Of 212 pretreatment isolates tested, 201 were inhibited by 0.06 micrograms or less of rosoxacin per ml. The MICs of rosoxacin for the remaining 11 isolates ranged up to 0.5 micrograms/ml. The incidence of adverse effects was relatively high (29% for the rosoxacin group versus 18% for the ampicillin group), but none of the reactions required medical intervention nor did they result in serious sequelae.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anand C. M., Kadis E. M. Evaluation of the Phadebact Gonococcus Test for confirmation of Neisseria gonorrhoeae. J Clin Microbiol. 1980 Jul;12(1):15–17. doi: 10.1128/jcm.12.1.15-17.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Calubiran O. V., Crisologo-Vizconde L. B., Tupasi T. E., Torres C. A., Limson B. M. Treatment of uncomplicated gonorrhoea in women. Comparison of rosoxacin and spectinomycin. Br J Vener Dis. 1982 Aug;58(4):231–235. doi: 10.1136/sti.58.4.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dobson R. A., O'Connor J. R., Poulin S. A., Kundsin R. B., Smith T. F., Came P. E. In vitro antimicrobial activity of rosoxacin against Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum. Antimicrob Agents Chemother. 1980 Nov;18(5):738–740. doi: 10.1128/aac.18.5.738. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Handsfield H. H., Judson F. N., Holmes K. K. Treatment of uncomplicated gonorrhea with rosoxacin. Antimicrob Agents Chemother. 1981 Nov;20(5):625–629. doi: 10.1128/aac.20.5.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Limson B. M., Macasaet R. K. Single oral dose rosoxacin in the treatment of gonorrhoea in males. J Int Med Res. 1982;10(1):42–45. doi: 10.1177/030006058201000109. [DOI] [PubMed] [Google Scholar]
- Walsh R. J., Scott R., Bittiner J. B., Shahidullah M., Slack R. C. Acrosoxacin in the treatment of uncomplicated gonorrhoea. Br J Vener Dis. 1983 Aug;59(4):242–244. doi: 10.1136/sti.59.4.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Warren C. A., Shannon K. P., Phillips I. In-vitro antigonococcal activity of rosoxacin (WIN 35213). Br J Vener Dis. 1981 Feb;57(1):33–35. doi: 10.1136/sti.57.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wiesner P. J., Holmes K. K., Sparling P. F., Maness M. J., Bear D. M., Gutman L. T., Karney W. W. Single doses of methacycline and doxycycline for gonorrhea: a cooperative study of the frequency and cause of treatment failure. J Infect Dis. 1973 Apr;127(4):461–466. doi: 10.1093/infdis/127.4.461. [DOI] [PubMed] [Google Scholar]